PURPOSE: The aim of the study was to investigate preferential initiation with the two most frequently used statins, simvastatin and atorvastatin, by patient characteristics over time. METHODS: Statin initiators without a statin prescription during the 365 days preceding the initiation from 1 January 1998 through 31 December 2004 were captured from the nation-wide Prescription Register in Finland. Associations of demographic factors and morbidities with atorvastatin versus simvastatin at initiation of statin treatment were analysed by a logistic regression model adjusted for significant covariates separately for each year. RESULTS: Of all new statin users in 1998, atorvastatin was chosen for 18% and simvastatin for 39%. In 2004, the corresponding figures were 32 and 38%. Atorvastatin was more likely than simvastatin to be initiated in younger age groups than in persons older than 74 years (reference group). Initiation with atorvastatin was less likely for people with than without coronary artery disease; adjusted odds ratios ranged from 0.62 to 0.73 over the years 1998-2003. CONCLUSION: Channelling of atorvastatin over simvastatin toward the younger and healthier population was found during the first 4 years after its launch in Finland. Channelling may lead to confounding by indication, which must be taken into account when designing pharmacoepidemiology studies on statins.
PURPOSE: The aim of the study was to investigate preferential initiation with the two most frequently used statins, simvastatin and atorvastatin, by patient characteristics over time. METHODS: Statin initiators without a statin prescription during the 365 days preceding the initiation from 1 January 1998 through 31 December 2004 were captured from the nation-wide Prescription Register in Finland. Associations of demographic factors and morbidities with atorvastatin versus simvastatin at initiation of statin treatment were analysed by a logistic regression model adjusted for significant covariates separately for each year. RESULTS: Of all new statin users in 1998, atorvastatin was chosen for 18% and simvastatin for 39%. In 2004, the corresponding figures were 32 and 38%. Atorvastatin was more likely than simvastatin to be initiated in younger age groups than in persons older than 74 years (reference group). Initiation with atorvastatin was less likely for people with than without coronary artery disease; adjusted odds ratios ranged from 0.62 to 0.73 over the years 1998-2003. CONCLUSION: Channelling of atorvastatin over simvastatin toward the younger and healthier population was found during the first 4 years after its launch in Finland. Channelling may lead to confounding by indication, which must be taken into account when designing pharmacoepidemiology studies on statins.
Authors: Zheng Zhou; Elham Rahme; Michal Abrahamowicz; Jack V Tu; Mark J Eisenberg; Karin Humphries; Peter C Austin; Louise Pilote Journal: CMAJ Date: 2005-04-26 Impact factor: 8.262
Authors: Fausto G Patino; Jeroan Allison; Jason Olivieri; Amy Mudano; Lucia Juarez; Sharina Person; Ted R Mikuls; Larry Moreland; Stacey H Kovac; Kenneth G Saag Journal: Arthritis Rheum Date: 2003-06-15
Authors: Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller Journal: Lancet Date: 2004 Aug 21-27 Impact factor: 79.321
Authors: J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto Journal: JAMA Date: 1998-05-27 Impact factor: 56.272
Authors: Brian L Strom; Rita Schinnar; Jason Karlawish; Sean Hennessy; Valerie Teal; Warren B Bilker Journal: JAMA Intern Med Date: 2015-08 Impact factor: 21.873
Authors: Arja Helin-Salmivaara; Piia Lavikainen; Emma Aarnio; Risto Huupponen; Maarit Jaana Korhonen Journal: PLoS One Date: 2014-03-10 Impact factor: 3.240
Authors: David M Kern; Setareh A Williams; Ozgur Tunceli; Catrin Wessman; Siting Zhou; Ned Pethick; Hanaa Elhefni; Frank Trudo Journal: Int J Chron Obstruct Pulmon Dis Date: 2014-07-18
Authors: Anke Neumann; Géric Maura; Alain Weill; Philippe Ricordeau; François Alla; Hubert Allemand Journal: Pharmacoepidemiol Drug Saf Date: 2013-12-02 Impact factor: 2.890